Skip Navigation

COVID-19 Update

Find a Doctor

Find a Researcher

Researchers

William Brian Dalton, M.D., Ph.D.

Photo of Dr. William Brian Dalton, M.D., Ph.D.
  • Assistant Professor of Oncology
Male

Expertise

Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myelodysplastic/Myeloproliferative Neoplasms

Research Interests

Myelodysplastic Syndromes (MDS); Acute Myeloid Leukemia (AML); RNA Splicing; Cancer Metabolism; Novel Therapeutic Vulnerabilities

Request an Appointment

Insurance Information

Maryland

410-955-8964

Outside of Maryland

410-464-6641
Request Appointment

International Patients

+1-410-502-7683
Request Appointment

Locations

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Appointment Phone: 410-955-8964
401 N. Broadway
Baltimore, MD 21231 map

Background

Dr. Dalton is an Assistant Professor of Oncology at The Johns Hopkins University School of Medicine.  He is active in the Division of Hematology Malignancies, Leukemia Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. 

Dr. Dalton is board certified in internal medicine and medical oncology.

Dr. Dalton has expertise in myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), and acute lymphoblastic leukemia (ALL).

Dr. Dalton received a combined M.D./Ph.D. degree through the Medical Scientist Training Program at Emory University School of Medicine. He completed a residency in internal medicine and a fellowship in medical oncology at Johns Hopkins. He joined the Johns Hopkins faculty in 2017.

Dr. Dalton is a member of the American Society of Hematology and the American Society of Clinical Oncology.

Dr. Dalton's primary research is to better understand the genetic events that drive MDS and AML and to develop new therapeutic approaches against these diseases.

...read more

Titles

  • Assistant Professor of Oncology

Departments / Divisions

Centers & Institutes

Education

Degrees

  • MD, Emory University School of Medicine (2010)

Residencies

  • Johns Hopkins University School of Medicine / Internal Medicine (2013)

Fellowships

  • Johns Hopkins University School of Medicine / Medical Oncology (2016)

Board Certifications

  • American Board of Internal Medicine / Internal Medicine (2013)
  • American Board of Internal Medicine / Medical Oncology (2016)

Research & Publications

Research Summary

As a physician-scientist in the Division of Hematologic Malignancies at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Dr. Dalton has a clinical specialty in myeloid leukemias and a research laboratory that focuses on the study of DNA mutations that drive those leukemias. In particular, he is working to better understand DNA mutations in the spliceosome, which occur in many patients with MDS and AML and are currently difficult to treat. He uses bone marrow and blood samples generously donated by patients, together with cell ‘models’ that he genetically engineers in the lab, to understand what these DNA mutations do and how they might be targeted with new treatments. His work has led to identification of vulnerabilities in cells containing these mutations that he aims to translate into novel therapeutic approaches in MDS and AML.

Clinical Trial Keywords

Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myeloproliferative Neoplasms, Acute Lymphoblastic Leukemia

Selected Publications

View all on Pubmed

Dalton WB, Helmenstine E, Pieterse L, Li B, Gocke CD, Donaldson J, Xiao Z, Gondek LP, Ghiaur G, Gojo I, Smith BD, Levis MJ, DeZern AE. The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicing. Blood Adv. 2020 Apr 14;4(7):1192-1196. PMID: 32211880 PMCID: PMC7160262 DOI: 10.1182/bloodadvances.2019001127

Dalton WB, Helmenstine E, Walsh N, Gondek LP, Kelkar DS, Read A, Natrajan R, Christenson ES, Roman B, Das S, Zhao L, Leone RD, Shinn D, Groginski T, Madugundu AK, Patil A, Zabransky DJ, Medford A, Lee J, Cole AJ, Rosen M, Thakar M, Ambinder A, Donaldson J, DeZern AE, Cravero K, Chu D, Madero-Marroquin R, Pandey A, Hurley PJ, Lauring J, Park BH. Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation. J Clin Invest. 2019 Aug 8;130:4708-4723. doi: 10.1172/JCI125022.

Dalton WB, Forde PM, Kang H, Connolly RM, Stearns V, Gocke CD, Eshleman JR, Axilbund J, Petry D, Geoghegan C, Wolff AC, Loeb DM, Pratilas CA, Meyer CF, Christenson ES, Slater SA, Ensminger J, Parsons HA, Park BH, Lauring J. Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board. JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.16.00046. Epub 2017 May 31.

Dalton WB, Yu B, Yang VW. p53 suppresses structural chromosome instability after mitotic arrest in human cells. Oncogene. 2010 Apr 1;29(13):1929-40. doi: 10.1038/onc.2009.477. Epub 2010 Jan 11.

Dalton WB, Nandan MO, Moore RT, Yang VW. Human cancer cells commonly acquire DNA damage during mitotic arrest. Cancer Res. 2007 Dec 15;67(24):11487-92.

Contact for Research Inquiries

1650 Orleans Street
Suite 288
Baltimore, MD 21287 map

Activities & Honors

Honors

  • Department of Defense Fellowship Breakthrough Award, 2016
  • Ladies Auxillary of the Veterans of Foreign Wars Postdoctoral Cancer Research Fellowship Award, 2016
  • American Society of Clinical Oncology Young Investigator Award, 2015
  • American Federation for Medical Research Student Award, 2004

Memberships

  • American Society of Hematology, 2017
  • American Society of Clinical Oncology, 2013

Professional Activities

  • Peer Reviewer, The Journal of Clinical Investigation, 2018
  • Coordinating Abstract Reviewer, American Society of Hematology, 2020

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

  • ...Loading ratings...
  • ... 
  • ... 
  • ... 
  • ... 
  • ... 

Comments

Loading...
Is this you? Edit Profile
back to top button